Welcome to our dedicated page for Invizyne Technologies news (Ticker: IZTC), a resource for investors and traders seeking the latest updates and insights on Invizyne Technologies stock.
The IZTC news page on Stock Titan provides an archive of public announcements and market communications related to Invizyne Technologies, Inc., the cell-free enzyme-based biomanufacturing company that later adopted the corporate name eXoZymes Inc. and now trades on Nasdaq under the ticker EXOZ. These historical news items document how the company presented its technology, projects, and capital markets milestones while its shares traded under the symbol IZTC.
In this archive, readers can review company press releases describing Invizyne’s cell-free, multi-step, enzyme-based systems for transforming natural or renewable resources into biochemicals, including active pharmaceutical ingredients (APIs), biofuels, food flavors, fragrances, and cosmetics. The news flow also covers key events such as the company’s initial public offering on the Nasdaq Capital Market, the start of trading under the IZTC symbol, and subsequent pricing and closing details of the IPO.
Other notable news items include Invizyne’s selection for a project supported by the U.S. Department of Defense’s BioMADE initiative to advance cell-free biomanufacturing of isobutanol for sustainable aviation fuel applications, as well as earlier grants from the U.S. Department of Energy’s Bioenergy Technologies Office. These stories outline the company’s stated vision for using cell-free enzymatic pathways as an alternative to traditional chemical synthesis, natural extraction, and cell-based synthetic biology.
The archive also contains announcements about the corporate name change from Invizyne Technologies, Inc. to eXoZymes Inc. and the associated Nasdaq ticker change from IZTC to EXOZ. Investors and researchers can use this page to trace the evolution of the company’s branding, its introduction of the “exozymes” concept, and its positioning within the broader field of synthetic biology and biomanufacturing. Bookmark this page to reference historical IZTC-related news when analyzing the company’s development over time.
Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.
eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced its corporate name change to eXoZymes, Inc. The company, currently trading under NASDAQ ticker IZTC, will change its ticker symbol to EXOZ, expected to take effect on February 12, 2025, pending final approvals.
The company will update its branding, including the corporate website, to reflect the new name. Existing shareholders are not required to take any action regarding the name and ticker symbol change. The CUSIP number for the company's common stock will remain unchanged.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.
Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.
Invizyne Technologies has announced the pricing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share, raising $15 million in gross proceeds. Trading will begin on Nasdaq under ticker 'IZTC' on November 12, 2024. The company granted a 45-day over-allotment option for 281,250 additional shares and will issue 184,375 warrants in a concurrent private placement. Proceeds will fund production expansion, business development, sales and marketing, loan repayment, and working capital. The offering is expected to close on November 13, 2024, with MDB Capital acting as underwriter.
FAQ
What is the current stock price of Invizyne Technologies (IZTC)?
What is the market cap of Invizyne Technologies (IZTC)?
